{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:32:32Z","timestamp":1792423952270,"version":"4.5.0"},"reference-count":59,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"851","funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL 166339"],"award-info":[{"award-number":["R01HL 166339"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA252174"],"award-info":[{"award-number":["K08CA252174"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.science.org"],"crossmark-restriction":true},"short-container-title":["Sci. Transl. Med."],"published-print":{"date-parts":[[2026,5,27]]},"abstract":"<jats:p>\n                    Traditional manufacturing of B cell maturation antigen (BCMA)\u2013targeted chimeric antigen receptor (CAR) T cell therapies is prolonged, leading to reduced patient access, T cell exhaustion, and consequently limiting therapeutic efficacy. To address this issue, we developed durcabtagene autoleucel, a BCMA-directed CAR T cell therapy manufactured using a rapid platform aimed at preserving T cell stemness. Here, we present the primary findings of part A of a phase 1 study (NCT04318327) of durcabtagene autoleucel in patients with relapsed\/refractory multiple myeloma (r\/r MM). The primary objective was safety; secondary objectives included response rates, cellular kinetics, immunogenicity, and manufacturing feasibility. Durcabtagene autoleucel was successfully manufactured for all 55 patients (median vein-to-vein time, 24 days) and given as a single infusion at one of four flat target doses (2.5\u00a0\u00d7\u00a010\n                    <jats:sup>6<\/jats:sup>\n                    to 20\u00a0\u00d7\u00a010\n                    <jats:sup>6<\/jats:sup>\n                    CAR T cells). Among all patients, the overall response rate was 98%, and the stringent complete response rate was 55%. Eighty percent of evaluable patients (35 of 44) achieved minimal residual disease negativity. There were no unexpected safety findings and no reports of delayed neurotoxicity. Immunophenotyping and transcriptomic analyses confirmed preservation of a stem-like phenotype in the manufactured final product. On the basis of the safety, efficacy, and cellular expansion results from the phase 1 trial, a phase 2 trial (NCT05172596) was initiated to further explore the efficacy and safety of durcabtagene autoleucel in heavily pretreated patients with aggressive r\/r MM.\n                  <\/jats:p>","DOI":"10.1126\/scitranslmed.adx1799","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:58:36Z","timestamp":1779904716000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1126","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":true,"given":"Adam S.","family":"Sperling","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA 02215, USA."},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA 02115, USA."},{"name":"Division of Hematology, Stanford University, Palo Alto, CA 94305, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":true,"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2711-5575","authenticated-orcid":true,"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA 02215, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6283-7859","authenticated-orcid":true,"given":"Alejandro","family":"Alonso","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA 02215, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0337-9867","authenticated-orcid":true,"given":"Shuntaro","family":"Ikegawa","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA 02215, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4087-1428","authenticated-orcid":true,"given":"Nina","family":"Orwitz","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-8968","authenticated-orcid":true,"given":"David S.","family":"Quinn","sequence":"additional","affiliation":[{"name":"Novartis BioMedical Research, Cambridge, MA 02139, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pearson","sequence":"additional","affiliation":[{"name":"Novartis BioMedical Research, Basel 4056, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexiu","family":"Bu","sequence":"additional","affiliation":[{"name":"Novartis BioMedical Research, Cambridge, MA 02139, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8285-957X","authenticated-orcid":true,"given":"Pedro","family":"Milanez-Almeida","sequence":"additional","affiliation":[{"name":"Novartis BioMedical Research, Cambridge, MA 02139, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mataraza","sequence":"additional","affiliation":[{"name":"Novartis BioMedical Research, Cambridge, MA 02139, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA 02215, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8014-706X","authenticated-orcid":true,"given":"Jessica","family":"Liegel","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA 02215, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, WI 53226, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Charles","sequence":"additional","affiliation":[{"name":"Novartis BioMedical Research, Cambridge, MA 02139, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Credi","sequence":"additional","affiliation":[{"name":"Novartis BioMedical Research, Cambridge, MA 02139, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":true,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA 02215, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-6822","authenticated-orcid":true,"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"De Vita","sequence":"additional","affiliation":[{"name":"Novartis BioMedical Research, Cambridge, MA 02139, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA 02215, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30110705"},{"key":"e_1_3_2_3_2","unstructured":"Cancer stat facts: Myeloma National Cancer Institute (2024); https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13264"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205154"},{"key":"e_1_3_2_6_2","first-page":"e45","article-title":"Long-term outcomes in patients with multiple myeloma: A retrospective analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)","volume":"2","author":"Verelst S. G. R.","year":"2018","unstructured":"S. G. R. Verelst, H. M. Blommestein, S. De Groot, S. Gonzalez-McQuire, L. DeCosta, J. B. de Raad, C. A. Uyl-de Groot, P. Sonneveld, Long-term outcomes in patients with multiple myeloma: A retrospective analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). Hema 2, e45 (2018).","journal-title":"Hema"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2022.138"},{"key":"e_1_3_2_8_2","unstructured":"CARVYKTI (ciltacabtagene autoleucel) prescribing information Janssen Biotech Inc. (2025); https:\/\/www.jnjlabels.com\/package-insert\/productmonograph\/prescribing-information\/CARVYKTI-pi.pdf."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_2_10_2","unstructured":"ABECMA (idecabtagene vicleucel) prescribing information Celgene Corporation a Bristol-Myers Squibb Company (2025); https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf."},{"key":"e_1_3_2_11_2","unstructured":"TECVAYLI (teclistamab-cqyv) prescribing information Janssen Biotech Inc. (2026); https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribinginformation\/TECVAYLI-pi.pdf."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152479"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.19.00086"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.02.007"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1276"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012416"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00763-8"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878209"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148390"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.006"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2446"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072530"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-97125-w"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065698"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024371"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016170"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188090"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201783"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10824-3"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025945"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186163"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1104771"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000600"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02129-y"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-1948"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00570-7"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06199-x"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.11.015"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.247"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adu5754"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02496-0"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146246"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giaa151"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.048"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1874-1"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25957-x"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2021.06.043"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01012-4"}],"container-title":["Science Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/scitranslmed.adx1799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:58:53Z","timestamp":1779904733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.adx1799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":59,"journal-issue":{"issue":"851","published-print":{"date-parts":[[2026,5,27]]}},"alternative-id":["10.1126\/scitranslmed.adx1799"],"URL":"https:\/\/doi.org\/10.1126\/scitranslmed.adx1799","relation":{},"ISSN":["1946-6234","1946-6242"],"issn-type":[{"value":"1946-6234","type":"print"},{"value":"1946-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"2025-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"eadx1799"}}